Serena Yun-Chen Tsai

Dr. Serena Yun-Chen Tsai

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Children
Verified
Journal Article
Open access
PDF file
MMMia Mologousis
Mia Mologousis
STSerena Yun-Chen Tsai
Serena Yun-Chen Tsai
KTKristin Tissera
Kristin Tissera
YLYakir S. Levin
Yakir S. Levin
Elena B. HawrylukElena B. Hawryluk
Elena B. Hawryluk
Congenital melanocytic nevi (CMN) carry an increased risk of melanoma and may be disfiguring, and consensus regarding treatment recommendations is lacking. While clinical monitoring is the standard of care, many caregivers are interested in its removal to prevent psychosocial burden or to decrease risk. Although melanoma can occur regardless of CMN removal, there are a variety of treatments that may offer improved cosmesis or local symptom control, including surgical excision, laser therapy, and other superficially destructive techniques. Regardless of the selected management, these patients are monitored for ongoing melanoma risk. An extensive discussion with families regarding the risks and benefits of observation versus active intervention is essential. To facilitate these discussions, we herein summarize current CMN management strategies and considerations.

21 August 2024 in Allergy
Verified
Journal Article
Open access
STSerena Yun-Chen Tsai
Serena Yun-Chen Tsai
JGJonathan M. Gaffin
Jonathan M. Gaffin
EHElena B. Hawryluk
Elena B. Hawryluk
HRHana B. Ruran
Hana B. Ruran
LBLisa M. Bartnikas
Lisa M. Bartnikas
KMKevin Sheng-Kai Ma
Kevin Sheng-Kai Ma
Background: Dupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD. Methods: In this population‐based cohort study, we utilized electronic health records from multiple healthcare organizations across the United States. Pediatric patients (<18 years of age) with a diagnosis of AD initiating dupilumab were propensity‐score matched 1:1 to those initiating other systemic agents (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, or systemic corticosteroids). The primary outcomes were new‐onset comorbidities emerging during the study period measured by the risk ratio (RR) and its confidence interval (CI). Subgroup analyses were stratified by age (0–5 years, 6–11 years, and 12–17 years), sex, and race. Results: A total of 3575 pediatric patients with AD treated with dupilumab were matched to 3575 patients treated with other systemic agents. The dupilumab cohort was associated with a lowered risk of new‐onset atopic comorbidities (including asthma [RR, 0.72; 95% CI, 0.59–0.89] and allergic rhinitis [RR, 0.62; 95% CI, 0.52–0.74]), infections (e.g., skin and soft tissue infection [RR, 0.70; 95% CI, 0.63–0.76] and respiratory tract infection [RR = 0.56; 95% CI, 0.51–0.61]), psychiatric disorders (e.g., mood disorder [RR, 0.52; 95% CI, 0.39–0.70] and anxiety [RR, 0.57; 95% CI, 0.46–0.70], sleep disturbance [RR, 0.60; 95% CI, 0.47–0.77]), neurologic and developmental disorders (e.g., attention deficit hyperactivity disorder [RR, 0.54; 95% CI, 0.38–0.75]). Furthermore, the positive effects are found to be more pronounced in younger children (aged 0–5 years) with AD. Conclusions: Treatment with dupilumab compared to systemic agents resulted in reductions in AD‐related comorbidities in pediatric patients.

19 June 2025 in European Respiratory Journal
Verified
Journal Article
Closed access
KMKevin Sheng-Kai Ma
Kevin Sheng-Kai Ma
BBBethany Brumbaugh
Bethany Brumbaugh
RSRebecca R. Saff
Rebecca R. Saff
WPWanda Phipatanakul
Wanda Phipatanakul
STSerena Yun-Chen Tsai
Serena Yun-Chen Tsai
SCSteven T. Chen
Steven T. Chen
Background: Dupilumab is approved for the treatment of atopic dermatitis, asthma, and other allergic diseases. Recent studies suggest that patients with atopic dermatitis receiving dupilumab are at a higher risk of developing cutaneous lymphoma. This study aimed to investigate the risk of lymphoma among patients with asthma receiving dupilumab. Methods: This population-based cohort study included patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024. Propensity score matching was used to balance baseline characteristics between groups. The primary outcome was new-onset lymphoma, and secondary outcomes included other malignancies and all-cause mortality. Results: A total of 14 936 dupilumab-treated and 734 126 ICS/LABA-treated patients with asthma were included. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19–2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82–11.53). There was no significant difference in incidence of other malignant neoplasms. Dupilumab was also associated with significantly lower all-cause mortality (328 versus 793 deaths, HR 0.65, 95% CI 0.57–0.74). Conclusions: Dupilumab treatment was associated with lower all-cause mortality among patients with asthma, despite increased risk of lymphoma, particularly T-cell and NK-cell lymphomas. These findings highlight the need for long-term surveillance and further research into the immunological mechanisms underlying dupilumab-associated lymphoma in asthma.

18 March 2024 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
STSerena Yun-Chen Tsai
Serena Yun-Chen Tsai
CHClaire E. Hamilton
Claire E. Hamilton
MMMia Mologousis
Mia Mologousis
Elena B. HawrylukElena B. Hawryluk
Elena B. Hawryluk

8 October 2025 in Pediatric Drugs
Verified
Journal Article
Open access
STSerena Yun-Chen Tsai
Serena Yun-Chen Tsai
AAAshwin N. Ananthakrishnan
Ashwin N. Ananthakrishnan
HWHarland S. Winter
Harland S. Winter
KMKevin Sheng-Kai Ma
Kevin Sheng-Kai Ma
Pediatric-onset inflammatory bowel diseases (IBD) are associated with an elevated risk of venous thromboembolism (VTE). However, data on the VTE risk in these patients treated with novel biologics, particularly vedolizumab, remain limited. To evaluate the association between vedolizumab and the risk of VTE compared with other biologics in patients with pediatric-onset Crohn's disease (CD) or ulcerative colitis (UC). We emulated a target trial using electronic health records from the TriNetX research network. The study included patients with CD or UC diagnosed before the age of 18 years who were treated with vedolizumab, ustekinumab, or anti-tumor necrosis factor (TNF) agents. Comparative groups were generated using 1:1 propensity-score matching based on relevant confounders. The primary outcome was the occurrence of any VTE within 12 months of follow-up. Cox proportional hazards models were used to compare the risk of VTE between vedolizumab-treated patients and those treated with anti-TNF agents and ustekinumab. A total of 1806 matched patient pairs were analyzed across four comparisons: patients treated with vedolizumab versus anti-TNF agents (CD = 407 pairs; UC = 443 pairs), and vedolizumab versus ustekinumab (CD = 563 pairs; UC = 393 pairs), respectively. Patients with CD receiving vedolizumab had a significantly higher risk of VTE compared with those receiving anti-TNF therapy (hazard ratio [HR] 8.63; 95% confidence interval [CI] 1.08-69.10; p = 0.014). A higher VTE risk was also observed in vedolizumab-treated patients with CD compared with those treated with ustekinumab (HR 4.64; 95% CI 1.35-15.97; p = 0.007). In contrast, no significant difference in VTE risk was found between vedolizumab and either comparator group in patients with UC. Treatment with vedolizumab was associated with a higher incidence of VTE than anti-TNF agents or ustekinumab among individuals with CD. Prospective cohort studies are warranted to validate the safety of biologic therapy for pediatric patients with CD.

20 August 2025 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
STSerena Yun-Chen Tsai
Serena Yun-Chen Tsai
HRHana B. Ruran
Hana B. Ruran
EHElena B. Hawryluk
Elena B. Hawryluk
WPWanda Phipatanakul
Wanda Phipatanakul
MOMichiko K. Oyoshi
Michiko K. Oyoshi
KMKevin Sheng-Kai Ma
Kevin Sheng-Kai Ma